Castration-Refractory Prostate Cancer: New Drugs in the Pipeline

被引：13
|
作者：
Schrijvers, Dirk [1 ]
Van Erps, Peter [2 ]
Cortvriend, Jim [2 ]
机构：
[1] Ziekenhuisnetwerk Antwerpen Middelheim, Dept Hematooncol, B-2020 Antwerp, Belgium
[2] Ziekenhuisnetwerk Antwerpen Middelheim, Dept Urol, B-2020 Antwerp, Belgium
来源：
ADVANCES IN THERAPY | 2010年 / 27卷 / 05期
关键词：
castration-refractory prostate cancer; docetaxel; cabazitaxel; abiraterone acetate; angiogenesis modulators; vaccines; PHASE-II TRIAL; ABIRATERONE ACETATE; 2ND-LINE CHEMOTHERAPY; PLUS PREDNISONE; CLINICAL-TRIAL; DOCETAXEL; INHIBITOR; CYP17; MITOXANTRONE; THALIDOMIDE;
D O I：
10.1007/s12325-010-0038-1
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naive or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.
引用
收藏
页码：285 / 296
页数：12
相关论文
共 50 条
  • [1] Castration-refractory prostate cancer: New drugs in the pipeline
    Dirk Schrijvers
    Peter Van Erps
    Jim Cortvriend
    Advances in Therapy, 2010, 27 : 285 - 296
  • [2] New Therapeutic Agents for Castration-Refractory Prostate Cancer
    Patten, David Y.
    Sartor, Oliver
    CLINICAL GENITOURINARY CANCER, 2009, 7 (02) : E4 - E6
  • [3] Castration-Refractory Prostate Cancer: New Therapies, New Questions
    Appleman, Leonard J.
    ONCOLOGY-NEW YORK, 2010, 24 (14): : 1318 - 1326
  • [4] Perspectives on mTOR Inhibitors for Castration-Refractory Prostate Cancer
    Burgio, Salvatore L.
    Fabbri, Francesco
    Seymour, Ian J.
    Zoli, Wainer
    Amadori, Dino
    De Giorgi, Ugo
    CURRENT CANCER DRUG TARGETS, 2012, 12 (08) : 940 - 949
  • [5] Modular therapy approach in metastatic castration-refractory prostate cancer
    B. Walter
    S. Rogenhofer
    M. Vogelhuber
    A. Berand
    W. F. Wieland
    R. Andreesen
    A. Reichle
    World Journal of Urology, 2010, 28 : 745 - 750
  • [6] Recent Advances in the Treatment for Metastatic Castration-Refractory Prostate Cancer
    Kwong, P. W. K.
    HONG KONG JOURNAL OF RADIOLOGY, 2013, 16 (04): : S44 - S49
  • [7] Change of the LHRH analogue in progressive castration-refractory prostate cancer
    Heidenreich, A.
    Porres, D.
    Epplen, R.
    van Erps, T.
    Pfister, D.
    UROLOGE, 2012, 51 (09): : 1282 - 1287
  • [8] Modular therapy approach in metastatic castration-refractory prostate cancer
    Walter, B.
    Rogenhofer, S.
    Vogelhuber, M.
    Berand, A.
    Wieland, W. F.
    Andreesen, R.
    Reichle, A.
    WORLD JOURNAL OF UROLOGY, 2010, 28 (06) : 745 - 750
  • [9] Efficacy of new agents on advanced castration-refractory prostate cancer with RAPID progression.
    Wu, Shenhong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [10] Efficacy of low-dose dexamethasone in castration-refractory prostate cancer
    Venkitaraman, Ramachandran
    Thomas, Karen
    Huddart, Robert A.
    Horwich, Alan
    Dearnaley, David P.
    Parker, Chris C.
    BJU INTERNATIONAL, 2008, 101 (04) : 440 - 443
12345